{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"93628.7","value":"113226.2"},{"groupId":"OG001","spread":"55518.5","value":"133378.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"14"}],"units":"Participants"}],"description":"CD38 receptor density assessed from bone marrow aspirates for responder and non-responders' participants was reported.","dispersionType":"Standard Deviation","groups":[{"description":"Participants treated with Isatuximab, with independent adjudication committee assessment response \\<PR.","id":"OG000","title":"Non-responder"},{"description":"Participants treated with Isatuximab, with independent adjudication committee assessment response \\>=PR.","id":"OG001","title":"Responder"}],"paramType":"MEAN","populationDescription":"Participants treated with Isatuximab (Phase 1 and 2) and evaluable for CD38 receptor density assessment. Here, 'overall number of participants analyzed' = participants with available data for this outcome measure.","reportingStatus":"POSTED","timeFrame":"At Baseline (Day 1)","title":"Phase 1 and 2: CD38 Receptor Density at Baseline","type":"SECONDARY","unitOfMeasure":"sMEC"}